董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Kristina M. Burow | 女 | Director | 51 | 85.00万美元 | 5781.96 | 2025-01-31 |
| Joshua Pinto | 男 | Director | 41 | 44.58万美元 | 4.86 | 2025-01-31 |
| Christopher Whitten Bernard | 男 | President, Chief Executive Officer and Director | 40 | 572.76万美元 | 3041.67 | 2025-01-31 |
| Clive A. Meanwell | 男 | Executive Chairman of the Board | 67 | 179.98万美元 | 3007.29 | 2025-01-31 |
| Paul L. Berns | 男 | Director | 58 | 127.50万美元 | 1997.23 | 2025-01-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Christopher J. Visioli | 男 | Chief Financial Officer and Chief Business Officer | 49 | 284.90万美元 | 12.92 | 2025-01-31 |
| Christopher Whitten Bernard | 男 | President, Chief Executive Officer and Director | 40 | 572.76万美元 | 3041.67 | 2025-01-31 |
| Steven Marso | 男 | Chief Medical Officer | 57 | 未披露 | 未持股 | 2025-01-31 |
| Brian Hubbard | 男 | Chief Scientific Officer | 52 | 101.55万美元 | 20.31 | 2025-01-31 |
| Clive A. Meanwell | 男 | Executive Chairman of the Board | 67 | 179.98万美元 | 3007.29 | 2025-01-31 |
董事简历
中英对照 | 中文 | 英文- Kristina M. Burow
-
Kristina M. Burow，自2013年5月起担任Metsera， Inc.董事会成员。自2011年11月以来，她一直担任ARCH Venture Partners（一家专注于早期技术公司的风险投资公司）的董事总经理，此前从2002年到2011年在ARCH担任过各种职务。自2020年1月以来，她一直担任neuora Therapeutics（一家上市的临床阶段生物制药公司）的联合创始人兼董事。自2018年2月以来，她还担任Boundless Bio， Inc.（上市的临床阶段肿瘤学公司）和Scholar Rock Holding Corporation（上市的生物制药公司）的董事。她目前担任各种私人生物技术和生物制药公司的董事会成员，包括Orbital Therapeutics、Mirador Therapeutics、Treeline Biosciences、Autobahn Therapeutics和Magnet Therapeutics等。此前，她是公共生物技术公司Receptos（被Celgene收购）的联合创始人和董事会成员。此前，她曾担任各种公共生物技术和生物制药公司（包括Beam Therapeutics， Gossamer Bio, UNITY biotechnology, Vir biotechnology Inc.）的董事会成员，以及各种私人生物技术和生物制药公司（包括Vividion Therapeutics， Inc.）的董事会成员，直到被拜耳收购。在加入ARCH之前，她是Novartis BioVenture Fund的合伙人，也是Novartis Research Foundation的基因组学研究所的早期员工，这两个研究所都是Novartis（一家上市制药公司）的一部分。她持有加州大学伯克利分校的化学学士学位、哥伦比亚大学的化学硕士学位和芝加哥大学布斯商学院的工商管理硕士学位。
Kristina M. Burow,has served as a member of Metsera, Inc. board of directors since May 2023. Ms. Burow has served as Managing Director of ARCH Venture Partners, a venture capital firm focused on early-stage technology companies, since November 2011 and previously held various roles at ARCH from 2002 to 2011. Ms. Burow has served as a Co-Founder and director of Neumora Therapeutics, a publicly-traded clinical-stage biopharmaceutical company, since January 2020. Ms. Burow also has served as a director of Boundless Bio, Inc., a publicly-traded clinical-stage oncology company, since February 2018, and Scholar Rock Holding Corporation, a publicly-traded biopharmaceutical company, since August 2014. Ms. Burow currently serves on the boards of directors of various private biotechnology and biopharmaceutical companies, including Orbital Therapeutics, Mirador Therapeutics, Treeline Biosciences, Autobahn Therapeutics, and Magnet Therapeutics among others. She previously was a co-founder and member of the board of directors of Receptos, a public biotechnology company, acquired by Celgene. Ms. Burow previously served on the board of directors of various public biotechnology and biopharmaceutical companies, including Beam Therapeutics, Gossamer Bio, UNITY Biotechnology, Vir Biotechnology Inc., among others and various private biotechnology and biopharmaceutical companies, including Vividion Therapeutics, Inc. until its acquisition by Bayer. Prior to joining ARCH, Ms. Burow was an Associate with the Novartis BioVenture Fund and an early employee at the Genomics Institute of the Novartis Research Foundation, both part of Novartis, a public pharmaceutical company. Ms. Burow holds a B.S. in Chemistry from the University of California, Berkeley, an M.A. in Chemistry from Columbia University and an M.B.A. from the University of Chicago Booth School of Business. - Kristina M. Burow，自2013年5月起担任Metsera， Inc.董事会成员。自2011年11月以来，她一直担任ARCH Venture Partners（一家专注于早期技术公司的风险投资公司）的董事总经理，此前从2002年到2011年在ARCH担任过各种职务。自2020年1月以来，她一直担任neuora Therapeutics（一家上市的临床阶段生物制药公司）的联合创始人兼董事。自2018年2月以来，她还担任Boundless Bio， Inc.（上市的临床阶段肿瘤学公司）和Scholar Rock Holding Corporation（上市的生物制药公司）的董事。她目前担任各种私人生物技术和生物制药公司的董事会成员，包括Orbital Therapeutics、Mirador Therapeutics、Treeline Biosciences、Autobahn Therapeutics和Magnet Therapeutics等。此前，她是公共生物技术公司Receptos（被Celgene收购）的联合创始人和董事会成员。此前，她曾担任各种公共生物技术和生物制药公司（包括Beam Therapeutics， Gossamer Bio, UNITY biotechnology, Vir biotechnology Inc.）的董事会成员，以及各种私人生物技术和生物制药公司（包括Vividion Therapeutics， Inc.）的董事会成员，直到被拜耳收购。在加入ARCH之前，她是Novartis BioVenture Fund的合伙人，也是Novartis Research Foundation的基因组学研究所的早期员工，这两个研究所都是Novartis（一家上市制药公司）的一部分。她持有加州大学伯克利分校的化学学士学位、哥伦比亚大学的化学硕士学位和芝加哥大学布斯商学院的工商管理硕士学位。
- Kristina M. Burow,has served as a member of Metsera, Inc. board of directors since May 2023. Ms. Burow has served as Managing Director of ARCH Venture Partners, a venture capital firm focused on early-stage technology companies, since November 2011 and previously held various roles at ARCH from 2002 to 2011. Ms. Burow has served as a Co-Founder and director of Neumora Therapeutics, a publicly-traded clinical-stage biopharmaceutical company, since January 2020. Ms. Burow also has served as a director of Boundless Bio, Inc., a publicly-traded clinical-stage oncology company, since February 2018, and Scholar Rock Holding Corporation, a publicly-traded biopharmaceutical company, since August 2014. Ms. Burow currently serves on the boards of directors of various private biotechnology and biopharmaceutical companies, including Orbital Therapeutics, Mirador Therapeutics, Treeline Biosciences, Autobahn Therapeutics, and Magnet Therapeutics among others. She previously was a co-founder and member of the board of directors of Receptos, a public biotechnology company, acquired by Celgene. Ms. Burow previously served on the board of directors of various public biotechnology and biopharmaceutical companies, including Beam Therapeutics, Gossamer Bio, UNITY Biotechnology, Vir Biotechnology Inc., among others and various private biotechnology and biopharmaceutical companies, including Vividion Therapeutics, Inc. until its acquisition by Bayer. Prior to joining ARCH, Ms. Burow was an Associate with the Novartis BioVenture Fund and an early employee at the Genomics Institute of the Novartis Research Foundation, both part of Novartis, a public pharmaceutical company. Ms. Burow holds a B.S. in Chemistry from the University of California, Berkeley, an M.A. in Chemistry from Columbia University and an M.B.A. from the University of Chicago Booth School of Business.
- Joshua Pinto
-
Joshua Pinto，自2024年9月起担任Metsera，Inc.董事会成员。Pinto博士自2021年6月起担任Neumora Therapeutics的首席财务官。在加入Neumora之前，Pinto博士曾于2015年4月至2021年6月在公共金融服务公司瑞士信贷担任越来越重要的职务，最近于2019年1月至2021年6月担任医疗保健投资银行业务总监，专注于生命科学领域，负责就合并、收购、重组、激进主义和融资为生物技术公司提供建议。Pinto博士曾于2014年至2015年任职于金融服务公司Piper Jaffray，担任医疗保健银行业的合伙人。在此之前，他于2013年至2014年在上市制药公司礼来从事全球外部研发工作。Pinto博士拥有路易斯安那州百年学院工商管理和生物化学学士学位、麦克马斯特大学金融硕士学位和麦克马斯特大学神经科学博士学位。
Joshua Pinto,has served as a member of Metsera, Inc. board of directors since September 2024. Dr. Pinto has served as chief financial officer of Neumora Therapeutics since June 2021. Prior to Neumora, Dr. Pinto held roles of increasing responsibility at Credit Suisse, a public financial services company, from April 2015 to June 2021, most recently serving as director of healthcare investment banking from January 2019 to June 2021, where he focused on the life sciences sector and was responsible for advising biotech companies on mergers, acquisitions, restructurings, activism and financing. Dr. Pinto worked for Piper Jaffray, a financial services company, as an associate in healthcare banking from 2014 to 2015. Before that, he worked in global external R&D at Eli Lilly, a public pharmaceutical company, from 2013 to 2014. Dr. Pinto holds a B.S. in Business Administration and Biochemistry from Centenary College of Louisiana, an M.B.A. in Finance from McMaster University and a Ph.D. in Neuroscience from McMaster University. - Joshua Pinto，自2024年9月起担任Metsera，Inc.董事会成员。Pinto博士自2021年6月起担任Neumora Therapeutics的首席财务官。在加入Neumora之前，Pinto博士曾于2015年4月至2021年6月在公共金融服务公司瑞士信贷担任越来越重要的职务，最近于2019年1月至2021年6月担任医疗保健投资银行业务总监，专注于生命科学领域，负责就合并、收购、重组、激进主义和融资为生物技术公司提供建议。Pinto博士曾于2014年至2015年任职于金融服务公司Piper Jaffray，担任医疗保健银行业的合伙人。在此之前，他于2013年至2014年在上市制药公司礼来从事全球外部研发工作。Pinto博士拥有路易斯安那州百年学院工商管理和生物化学学士学位、麦克马斯特大学金融硕士学位和麦克马斯特大学神经科学博士学位。
- Joshua Pinto,has served as a member of Metsera, Inc. board of directors since September 2024. Dr. Pinto has served as chief financial officer of Neumora Therapeutics since June 2021. Prior to Neumora, Dr. Pinto held roles of increasing responsibility at Credit Suisse, a public financial services company, from April 2015 to June 2021, most recently serving as director of healthcare investment banking from January 2019 to June 2021, where he focused on the life sciences sector and was responsible for advising biotech companies on mergers, acquisitions, restructurings, activism and financing. Dr. Pinto worked for Piper Jaffray, a financial services company, as an associate in healthcare banking from 2014 to 2015. Before that, he worked in global external R&D at Eli Lilly, a public pharmaceutical company, from 2013 to 2014. Dr. Pinto holds a B.S. in Business Administration and Biochemistry from Centenary College of Louisiana, an M.B.A. in Finance from McMaster University and a Ph.D. in Neuroscience from McMaster University.
- Christopher Whitten Bernard
-
Christopher Whitten Bernard，首席执行官，自2024年9月起担任我们的董事会成员。从2023年3月到2024年9月，Bernard先生担任我们的首席运营官。Bernard先生是生命科学投资公司Population Health Partners，L.P.的联合创始人，自2020年5月起担任其普通合伙人Population Health Partners GP，LLC的管理成员。Bernard先生此前曾于2020年5月至2024年9月担任Population Health Partners，L.P.的副董事长兼管理合伙人。Bernard先生于2019年1月至2020年4月期间担任专注于解决心血管疾病的生物制药公司The Medicines Company商业战略和业务发展高级副总裁。在此之前，Bernard先生曾于2013年至2018年在麦肯锡公司担任过多种顾问职务。Bernard先生拥有西北大学家乐氏管理学院的工商管理硕士学位和布朗大学的音乐学士学位。
Christopher Whitten Bernard,has served as Metsera, Inc. President, Chief Executive Officer and a member of Metsera, Inc. board of directors since September 2024. From March 2023 to September 2024, Mr. Bernard served as Metsera, Inc. Chief Operating Officer. Mr. Bernard is a Co-Founder of Population Health Partners, L.P., a life sciences investment firm, and, since May 2020 has served as a managing member of Population Health Partners GP, LLC, its General Partner. Mr. Bernard previously served as Vice Chairman and Managing Partner of Population Health Partners, L.P. from May 2020 to September 2024. Mr. Bernard served as Senior Vice President, Commercial Strategy and Business Development of The Medicines Company, a biopharmaceutical company focused on addressing cardiovascular disease, from January 2019 to April 2020. Prior to that, Mr. Bernard served in a variety of roles as a Consultant at McKinsey & Company from 2013 to 2018. Mr. Bernard holds an M.B.A. from the Kellogg School of Management at Northwestern University and a B.A. in Music from Brown University. - Christopher Whitten Bernard，首席执行官，自2024年9月起担任我们的董事会成员。从2023年3月到2024年9月，Bernard先生担任我们的首席运营官。Bernard先生是生命科学投资公司Population Health Partners，L.P.的联合创始人，自2020年5月起担任其普通合伙人Population Health Partners GP，LLC的管理成员。Bernard先生此前曾于2020年5月至2024年9月担任Population Health Partners，L.P.的副董事长兼管理合伙人。Bernard先生于2019年1月至2020年4月期间担任专注于解决心血管疾病的生物制药公司The Medicines Company商业战略和业务发展高级副总裁。在此之前，Bernard先生曾于2013年至2018年在麦肯锡公司担任过多种顾问职务。Bernard先生拥有西北大学家乐氏管理学院的工商管理硕士学位和布朗大学的音乐学士学位。
- Christopher Whitten Bernard,has served as Metsera, Inc. President, Chief Executive Officer and a member of Metsera, Inc. board of directors since September 2024. From March 2023 to September 2024, Mr. Bernard served as Metsera, Inc. Chief Operating Officer. Mr. Bernard is a Co-Founder of Population Health Partners, L.P., a life sciences investment firm, and, since May 2020 has served as a managing member of Population Health Partners GP, LLC, its General Partner. Mr. Bernard previously served as Vice Chairman and Managing Partner of Population Health Partners, L.P. from May 2020 to September 2024. Mr. Bernard served as Senior Vice President, Commercial Strategy and Business Development of The Medicines Company, a biopharmaceutical company focused on addressing cardiovascular disease, from January 2019 to April 2020. Prior to that, Mr. Bernard served in a variety of roles as a Consultant at McKinsey & Company from 2013 to 2018. Mr. Bernard holds an M.B.A. from the Kellogg School of Management at Northwestern University and a B.A. in Music from Brown University.
- Clive A. Meanwell
-
Clive A. Meanwell是一位创始人，自1996年以来一直担任董事。他自2012年2月起担任Metsera，Inc.首席执行官，2009年10月至2012年2月担任Metsera，Inc.首席执行官兼总裁，2004年8月至2009年10月担任Metsera，Inc.总裁，2004年8月至2004年12月担任Metsera，Inc.执行董事长，2001年9月至2004年8月担任Metsera，Inc.执行董事长，1996年至2001年9月担任Metsera，Inc.首席执行官兼总裁。Meanwell博士还曾于2001年9月至2015年8月担任Metsera，Inc.董事会主席。Meanwell博士是瑞士投资公司BB Biotech的副董事长。从1995年到1996年，Meanwell博士是风险投资公司MPM Capital，L.P.的合伙人兼董事总经理。1986-1995年，Meanwell博士在制药公司Hoffmann-La Roche，Inc.担任过多个职位，包括1992-1995年的高级副总裁、1991-1992年的副总裁和1986-1991年的产品开发总监。Meanwell博士在英国伯明翰大学获得医学博士、工商管理硕士和博士学位（M.D。）。
Clive A. Meanwell,has served as Metsera, Inc. Executive Chairman of the Board of Directors since September 2024 and as Metsera, Inc. Founder and a member of Metsera, Inc. board of directors since Metsera, Inc. inception in June 2022. Dr. Meanwell previously served as Metsera, Inc. Chief Executive Officer from March 2023 to September 2024. Dr. Meanwell has served as a director of Fractyl Health, Inc., a publicly-held metabolic therapeutics company since June 2021. Dr. Meanwell is a Co-Founder of Population Health Partners, L.P., a life sciences investment firm, and, since May 2020 has served as its Chairman and Managing Partner, as well as a managing member of Population Health Partners GP, LLC, its General Partner. Since January 2003, Dr. Meanwell has served as Vice Chairman of BB Biotech AG, a publicly-held Swiss biotechnology investment company, where he has also served as a director since 2004. Dr. Meanwell founded and served as Executive Chairman, Chief Executive Officer, and Director of The Medicines Company, a biopharmaceutical company focused on cardiovascular and infectious diseases and surgery, from 1997 to December 2018, and as a Director and Chief Innovation Officer from December 2018 to January 2020, prior to its sale to Novartis in January 2020. Prior to his founding of The Medicines Company, Dr. Meanwell was a Partner at MPM Capital, a venture capital firm. Before then, he held leadership roles of increasing scope at Roche worldwide, culminating as Senior Vice President and Director in the pharmaceutical division. Dr. Meanwell began his career in cancer treatment and research. He holds an M.B., Ch.B. and M.D. magna cum laude from the University of Birmingham, United Kingdom. - Clive A. Meanwell是一位创始人，自1996年以来一直担任董事。他自2012年2月起担任Metsera，Inc.首席执行官，2009年10月至2012年2月担任Metsera，Inc.首席执行官兼总裁，2004年8月至2009年10月担任Metsera，Inc.总裁，2004年8月至2004年12月担任Metsera，Inc.执行董事长，2001年9月至2004年8月担任Metsera，Inc.执行董事长，1996年至2001年9月担任Metsera，Inc.首席执行官兼总裁。Meanwell博士还曾于2001年9月至2015年8月担任Metsera，Inc.董事会主席。Meanwell博士是瑞士投资公司BB Biotech的副董事长。从1995年到1996年，Meanwell博士是风险投资公司MPM Capital，L.P.的合伙人兼董事总经理。1986-1995年，Meanwell博士在制药公司Hoffmann-La Roche，Inc.担任过多个职位，包括1992-1995年的高级副总裁、1991-1992年的副总裁和1986-1991年的产品开发总监。Meanwell博士在英国伯明翰大学获得医学博士、工商管理硕士和博士学位（M.D。）。
- Clive A. Meanwell,has served as Metsera, Inc. Executive Chairman of the Board of Directors since September 2024 and as Metsera, Inc. Founder and a member of Metsera, Inc. board of directors since Metsera, Inc. inception in June 2022. Dr. Meanwell previously served as Metsera, Inc. Chief Executive Officer from March 2023 to September 2024. Dr. Meanwell has served as a director of Fractyl Health, Inc., a publicly-held metabolic therapeutics company since June 2021. Dr. Meanwell is a Co-Founder of Population Health Partners, L.P., a life sciences investment firm, and, since May 2020 has served as its Chairman and Managing Partner, as well as a managing member of Population Health Partners GP, LLC, its General Partner. Since January 2003, Dr. Meanwell has served as Vice Chairman of BB Biotech AG, a publicly-held Swiss biotechnology investment company, where he has also served as a director since 2004. Dr. Meanwell founded and served as Executive Chairman, Chief Executive Officer, and Director of The Medicines Company, a biopharmaceutical company focused on cardiovascular and infectious diseases and surgery, from 1997 to December 2018, and as a Director and Chief Innovation Officer from December 2018 to January 2020, prior to its sale to Novartis in January 2020. Prior to his founding of The Medicines Company, Dr. Meanwell was a Partner at MPM Capital, a venture capital firm. Before then, he held leadership roles of increasing scope at Roche worldwide, culminating as Senior Vice President and Director in the pharmaceutical division. Dr. Meanwell began his career in cancer treatment and research. He holds an M.B., Ch.B. and M.D. magna cum laude from the University of Birmingham, United Kingdom.
- Paul L. Berns
-
Paul L. Berns，自2013年5月起担任Metsera， Inc.董事会成员。自2021年以来，Berns先生一直担任ARCH Venture Partners（一家专注于早期技术公司的风险投资公司）的董事总经理，此前从2018年到2021年在ARCH担任各种职务。他是neuora Therapeutics（上市的临床阶段生物制药公司）的创始人、首席执行官和董事会主席（从2020年到2023年）。Berns先生自2018年3月起担任Unity Biotechnology， Inc.（上市的生物技术公司）的董事。他还担任生物制药公司EQRx， Inc.（从2020年1月到2023年被Revolution Medicines， Inc.收购）、上市制药公司Jazz Pharmaceuticals plc（从2010年到2021年7月）和上市临床阶段生物制药公司Vyne Therapeutics Inc.（从2017年11月到2020年3月）的董事。他持有Wisconsin大学的经济学学士学位。
Paul L. Berns,has served as a member of Metsera, Inc. board of directors since May 2023. Mr. Berns has served as a managing director of ARCH Venture Partners, a venture capital firm focused on early-stage technology companies, since 2021 and previously held various roles at ARCH from 2018 to 2021. Mr. Berns was the founder and served as chief executive officer and chairman of the board of directors of Neumora Therapeutics, a publicly-traded clinical-stage biopharmaceutical company, from 2020 to 2023. Mr. Berns has served as a director of Unity Biotechnology, Inc., a publicly-traded biotechnology company, since March 2018. He also served as a director of EQRx, Inc., a biopharmaceutical company, from January 2020 up to its acquisition by Revolution Medicines, Inc. in 2023, Jazz Pharmaceuticals plc, a publicly-traded pharmaceutical company, from 2010 to July 2021, and Vyne Therapeutics Inc., a publicly-traded clinical-stage biopharmaceutical company, from November 2017 to March 2020. Mr. Berns holds a B.S. in Economics from the University of Wisconsin. - Paul L. Berns，自2013年5月起担任Metsera， Inc.董事会成员。自2021年以来，Berns先生一直担任ARCH Venture Partners（一家专注于早期技术公司的风险投资公司）的董事总经理，此前从2018年到2021年在ARCH担任各种职务。他是neuora Therapeutics（上市的临床阶段生物制药公司）的创始人、首席执行官和董事会主席（从2020年到2023年）。Berns先生自2018年3月起担任Unity Biotechnology， Inc.（上市的生物技术公司）的董事。他还担任生物制药公司EQRx， Inc.（从2020年1月到2023年被Revolution Medicines， Inc.收购）、上市制药公司Jazz Pharmaceuticals plc（从2010年到2021年7月）和上市临床阶段生物制药公司Vyne Therapeutics Inc.（从2017年11月到2020年3月）的董事。他持有Wisconsin大学的经济学学士学位。
- Paul L. Berns,has served as a member of Metsera, Inc. board of directors since May 2023. Mr. Berns has served as a managing director of ARCH Venture Partners, a venture capital firm focused on early-stage technology companies, since 2021 and previously held various roles at ARCH from 2018 to 2021. Mr. Berns was the founder and served as chief executive officer and chairman of the board of directors of Neumora Therapeutics, a publicly-traded clinical-stage biopharmaceutical company, from 2020 to 2023. Mr. Berns has served as a director of Unity Biotechnology, Inc., a publicly-traded biotechnology company, since March 2018. He also served as a director of EQRx, Inc., a biopharmaceutical company, from January 2020 up to its acquisition by Revolution Medicines, Inc. in 2023, Jazz Pharmaceuticals plc, a publicly-traded pharmaceutical company, from 2010 to July 2021, and Vyne Therapeutics Inc., a publicly-traded clinical-stage biopharmaceutical company, from November 2017 to March 2020. Mr. Berns holds a B.S. in Economics from the University of Wisconsin.
高管简历
中英对照 | 中文 | 英文- Christopher J. Visioli
ChristopherJ.Visioli自2018年3月以来一直担任我们的首席财务官兼财务主管。他此前曾担任我们的高级副总裁，财务战略（2015年1月至2018年3月），以及我们的Vice President心血管护理（2013年1月至2014年12月）。Visioli先生于2003年6月加入我们，并在该组织担任过各种领导职务，包括心血管护理单位的财务，业务发展，投资者关系，战略，计划和业务领导。他曾领导该组织的许多努力，除了领导长期战略和财务规划工作外，还获得产品和建立伙伴关系。在加入我们之前和进入商学院之前，Visioli先生是Ernst&Young LLP的管理顾问。Visioli先生在康奈尔大学（Cornell University）获得电气工程学士学位，并在哥伦比亚商学院（Columbia Business School）获得工商管理硕士学位。
Christopher J. Visioli,has served as Metsera, Inc. Chief Financial Officer since October 2024 and Chief Business Officer since August 2023. Since September 2020, Mr. Visioli has also served as Partner of Population Health Partners, L.P., a life sciences investment firm. Prior to that, Mr. Visioli held a number of leadership roles at The Medicines Company from June 2003 to May 2020, most recently as its Chief Financial Officer. Prior to that, Mr. Visioli was a management consultant at Ernst & Young. Mr. Visioli holds an M.B.A. from Columbia Business School and a B.S. in Electrical Engineering from Cornell University.- ChristopherJ.Visioli自2018年3月以来一直担任我们的首席财务官兼财务主管。他此前曾担任我们的高级副总裁，财务战略（2015年1月至2018年3月），以及我们的Vice President心血管护理（2013年1月至2014年12月）。Visioli先生于2003年6月加入我们，并在该组织担任过各种领导职务，包括心血管护理单位的财务，业务发展，投资者关系，战略，计划和业务领导。他曾领导该组织的许多努力，除了领导长期战略和财务规划工作外，还获得产品和建立伙伴关系。在加入我们之前和进入商学院之前，Visioli先生是Ernst&Young LLP的管理顾问。Visioli先生在康奈尔大学（Cornell University）获得电气工程学士学位，并在哥伦比亚商学院（Columbia Business School）获得工商管理硕士学位。
- Christopher J. Visioli,has served as Metsera, Inc. Chief Financial Officer since October 2024 and Chief Business Officer since August 2023. Since September 2020, Mr. Visioli has also served as Partner of Population Health Partners, L.P., a life sciences investment firm. Prior to that, Mr. Visioli held a number of leadership roles at The Medicines Company from June 2003 to May 2020, most recently as its Chief Financial Officer. Prior to that, Mr. Visioli was a management consultant at Ernst & Young. Mr. Visioli holds an M.B.A. from Columbia Business School and a B.S. in Electrical Engineering from Cornell University.
- Christopher Whitten Bernard
Christopher Whitten Bernard，首席执行官，自2024年9月起担任我们的董事会成员。从2023年3月到2024年9月，Bernard先生担任我们的首席运营官。Bernard先生是生命科学投资公司Population Health Partners，L.P.的联合创始人，自2020年5月起担任其普通合伙人Population Health Partners GP，LLC的管理成员。Bernard先生此前曾于2020年5月至2024年9月担任Population Health Partners，L.P.的副董事长兼管理合伙人。Bernard先生于2019年1月至2020年4月期间担任专注于解决心血管疾病的生物制药公司The Medicines Company商业战略和业务发展高级副总裁。在此之前，Bernard先生曾于2013年至2018年在麦肯锡公司担任过多种顾问职务。Bernard先生拥有西北大学家乐氏管理学院的工商管理硕士学位和布朗大学的音乐学士学位。
Christopher Whitten Bernard,has served as Metsera, Inc. President, Chief Executive Officer and a member of Metsera, Inc. board of directors since September 2024. From March 2023 to September 2024, Mr. Bernard served as Metsera, Inc. Chief Operating Officer. Mr. Bernard is a Co-Founder of Population Health Partners, L.P., a life sciences investment firm, and, since May 2020 has served as a managing member of Population Health Partners GP, LLC, its General Partner. Mr. Bernard previously served as Vice Chairman and Managing Partner of Population Health Partners, L.P. from May 2020 to September 2024. Mr. Bernard served as Senior Vice President, Commercial Strategy and Business Development of The Medicines Company, a biopharmaceutical company focused on addressing cardiovascular disease, from January 2019 to April 2020. Prior to that, Mr. Bernard served in a variety of roles as a Consultant at McKinsey & Company from 2013 to 2018. Mr. Bernard holds an M.B.A. from the Kellogg School of Management at Northwestern University and a B.A. in Music from Brown University.- Christopher Whitten Bernard，首席执行官，自2024年9月起担任我们的董事会成员。从2023年3月到2024年9月，Bernard先生担任我们的首席运营官。Bernard先生是生命科学投资公司Population Health Partners，L.P.的联合创始人，自2020年5月起担任其普通合伙人Population Health Partners GP，LLC的管理成员。Bernard先生此前曾于2020年5月至2024年9月担任Population Health Partners，L.P.的副董事长兼管理合伙人。Bernard先生于2019年1月至2020年4月期间担任专注于解决心血管疾病的生物制药公司The Medicines Company商业战略和业务发展高级副总裁。在此之前，Bernard先生曾于2013年至2018年在麦肯锡公司担任过多种顾问职务。Bernard先生拥有西北大学家乐氏管理学院的工商管理硕士学位和布朗大学的音乐学士学位。
- Christopher Whitten Bernard,has served as Metsera, Inc. President, Chief Executive Officer and a member of Metsera, Inc. board of directors since September 2024. From March 2023 to September 2024, Mr. Bernard served as Metsera, Inc. Chief Operating Officer. Mr. Bernard is a Co-Founder of Population Health Partners, L.P., a life sciences investment firm, and, since May 2020 has served as a managing member of Population Health Partners GP, LLC, its General Partner. Mr. Bernard previously served as Vice Chairman and Managing Partner of Population Health Partners, L.P. from May 2020 to September 2024. Mr. Bernard served as Senior Vice President, Commercial Strategy and Business Development of The Medicines Company, a biopharmaceutical company focused on addressing cardiovascular disease, from January 2019 to April 2020. Prior to that, Mr. Bernard served in a variety of roles as a Consultant at McKinsey & Company from 2013 to 2018. Mr. Bernard holds an M.B.A. from the Kellogg School of Management at Northwestern University and a B.A. in Music from Brown University.
- Steven Marso
Steven Marso，Marso博士在2016年至2023年期间担任大型医疗保健提供商美国医院公司心血管服务的医疗总监，在那里他领导了整个美国中部分部所有与心血管相关的工作。在此之前，Marso博士曾于2014年至2016年担任得克萨斯大学SW医学中心（一家医院/教育中心）的介入心脏病学主任/医学教授。Marso博士拥有堪萨斯大学的医学博士学位和堪萨斯大学的细胞生物学学士学位。
Steven Marso,has served as Metsera, Inc. Chief Medical Officer since May 2023. Prior to joining Metsera, Inc. , Dr. Marso served as Medical Director of Cardiovascular Services of Hospital Corporation of America, a large health care provider, from 2016 to 2023, where he led all cardiovascular-related efforts across the Mid America division. Prior to that, Dr. Marso served as Director of Interventional Cardiology/Professor of Medicine of University of Texas SW Medical Center, a hospital/educational center, from 2014 to 2016. Dr. Marso holds an M.D. from the University of Kansas and a Bachelor in Cellular Biology from University of Kansas.- Steven Marso，Marso博士在2016年至2023年期间担任大型医疗保健提供商美国医院公司心血管服务的医疗总监，在那里他领导了整个美国中部分部所有与心血管相关的工作。在此之前，Marso博士曾于2014年至2016年担任得克萨斯大学SW医学中心（一家医院/教育中心）的介入心脏病学主任/医学教授。Marso博士拥有堪萨斯大学的医学博士学位和堪萨斯大学的细胞生物学学士学位。
- Steven Marso,has served as Metsera, Inc. Chief Medical Officer since May 2023. Prior to joining Metsera, Inc. , Dr. Marso served as Medical Director of Cardiovascular Services of Hospital Corporation of America, a large health care provider, from 2016 to 2023, where he led all cardiovascular-related efforts across the Mid America division. Prior to that, Dr. Marso served as Director of Interventional Cardiology/Professor of Medicine of University of Texas SW Medical Center, a hospital/educational center, from 2014 to 2016. Dr. Marso holds an M.D. from the University of Kansas and a Bachelor in Cellular Biology from University of Kansas.
- Brian Hubbard
Brian Hubbard，Dr. Hubbard曾于2018年2月至2024年4月担任临床阶段生物技术公司Anji Pharmaceuticals的首席执行官。在此之前，Hubbard博士曾于2015年9月至2021年11月担任发现阶段生物技术公司Dogma Therapeutics的首席执行官。Hubbard博士拥有伊利诺伊大学化学博士学位和William & Mary化学学士学位。
Brian Hubbard,has served as Metsera, Inc. Chief Scientific Officer since May 2023. Prior to joining Metsera, Inc. , Dr. Hubbard served as Chief Executive Officer of Anji Pharmaceuticals, a clinical-stage biotechnology company, from February 2018 to April 2024. Prior to that, Dr. Hubbard served as Chief Executive Officer of Dogma Therapeutics, a discovery stage biotechnology company, from September 2015 to November 2021. Dr. Hubbard holds a Ph.D. in Chemistry from the University of Illinois and a B.S. in Chemistry from William & Mary.- Brian Hubbard，Dr. Hubbard曾于2018年2月至2024年4月担任临床阶段生物技术公司Anji Pharmaceuticals的首席执行官。在此之前，Hubbard博士曾于2015年9月至2021年11月担任发现阶段生物技术公司Dogma Therapeutics的首席执行官。Hubbard博士拥有伊利诺伊大学化学博士学位和William & Mary化学学士学位。
- Brian Hubbard,has served as Metsera, Inc. Chief Scientific Officer since May 2023. Prior to joining Metsera, Inc. , Dr. Hubbard served as Chief Executive Officer of Anji Pharmaceuticals, a clinical-stage biotechnology company, from February 2018 to April 2024. Prior to that, Dr. Hubbard served as Chief Executive Officer of Dogma Therapeutics, a discovery stage biotechnology company, from September 2015 to November 2021. Dr. Hubbard holds a Ph.D. in Chemistry from the University of Illinois and a B.S. in Chemistry from William & Mary.
- Clive A. Meanwell
Clive A. Meanwell是一位创始人，自1996年以来一直担任董事。他自2012年2月起担任Metsera，Inc.首席执行官，2009年10月至2012年2月担任Metsera，Inc.首席执行官兼总裁，2004年8月至2009年10月担任Metsera，Inc.总裁，2004年8月至2004年12月担任Metsera，Inc.执行董事长，2001年9月至2004年8月担任Metsera，Inc.执行董事长，1996年至2001年9月担任Metsera，Inc.首席执行官兼总裁。Meanwell博士还曾于2001年9月至2015年8月担任Metsera，Inc.董事会主席。Meanwell博士是瑞士投资公司BB Biotech的副董事长。从1995年到1996年，Meanwell博士是风险投资公司MPM Capital，L.P.的合伙人兼董事总经理。1986-1995年，Meanwell博士在制药公司Hoffmann-La Roche，Inc.担任过多个职位，包括1992-1995年的高级副总裁、1991-1992年的副总裁和1986-1991年的产品开发总监。Meanwell博士在英国伯明翰大学获得医学博士、工商管理硕士和博士学位（M.D。）。
Clive A. Meanwell,has served as Metsera, Inc. Executive Chairman of the Board of Directors since September 2024 and as Metsera, Inc. Founder and a member of Metsera, Inc. board of directors since Metsera, Inc. inception in June 2022. Dr. Meanwell previously served as Metsera, Inc. Chief Executive Officer from March 2023 to September 2024. Dr. Meanwell has served as a director of Fractyl Health, Inc., a publicly-held metabolic therapeutics company since June 2021. Dr. Meanwell is a Co-Founder of Population Health Partners, L.P., a life sciences investment firm, and, since May 2020 has served as its Chairman and Managing Partner, as well as a managing member of Population Health Partners GP, LLC, its General Partner. Since January 2003, Dr. Meanwell has served as Vice Chairman of BB Biotech AG, a publicly-held Swiss biotechnology investment company, where he has also served as a director since 2004. Dr. Meanwell founded and served as Executive Chairman, Chief Executive Officer, and Director of The Medicines Company, a biopharmaceutical company focused on cardiovascular and infectious diseases and surgery, from 1997 to December 2018, and as a Director and Chief Innovation Officer from December 2018 to January 2020, prior to its sale to Novartis in January 2020. Prior to his founding of The Medicines Company, Dr. Meanwell was a Partner at MPM Capital, a venture capital firm. Before then, he held leadership roles of increasing scope at Roche worldwide, culminating as Senior Vice President and Director in the pharmaceutical division. Dr. Meanwell began his career in cancer treatment and research. He holds an M.B., Ch.B. and M.D. magna cum laude from the University of Birmingham, United Kingdom.- Clive A. Meanwell是一位创始人，自1996年以来一直担任董事。他自2012年2月起担任Metsera，Inc.首席执行官，2009年10月至2012年2月担任Metsera，Inc.首席执行官兼总裁，2004年8月至2009年10月担任Metsera，Inc.总裁，2004年8月至2004年12月担任Metsera，Inc.执行董事长，2001年9月至2004年8月担任Metsera，Inc.执行董事长，1996年至2001年9月担任Metsera，Inc.首席执行官兼总裁。Meanwell博士还曾于2001年9月至2015年8月担任Metsera，Inc.董事会主席。Meanwell博士是瑞士投资公司BB Biotech的副董事长。从1995年到1996年，Meanwell博士是风险投资公司MPM Capital，L.P.的合伙人兼董事总经理。1986-1995年，Meanwell博士在制药公司Hoffmann-La Roche，Inc.担任过多个职位，包括1992-1995年的高级副总裁、1991-1992年的副总裁和1986-1991年的产品开发总监。Meanwell博士在英国伯明翰大学获得医学博士、工商管理硕士和博士学位（M.D。）。
- Clive A. Meanwell,has served as Metsera, Inc. Executive Chairman of the Board of Directors since September 2024 and as Metsera, Inc. Founder and a member of Metsera, Inc. board of directors since Metsera, Inc. inception in June 2022. Dr. Meanwell previously served as Metsera, Inc. Chief Executive Officer from March 2023 to September 2024. Dr. Meanwell has served as a director of Fractyl Health, Inc., a publicly-held metabolic therapeutics company since June 2021. Dr. Meanwell is a Co-Founder of Population Health Partners, L.P., a life sciences investment firm, and, since May 2020 has served as its Chairman and Managing Partner, as well as a managing member of Population Health Partners GP, LLC, its General Partner. Since January 2003, Dr. Meanwell has served as Vice Chairman of BB Biotech AG, a publicly-held Swiss biotechnology investment company, where he has also served as a director since 2004. Dr. Meanwell founded and served as Executive Chairman, Chief Executive Officer, and Director of The Medicines Company, a biopharmaceutical company focused on cardiovascular and infectious diseases and surgery, from 1997 to December 2018, and as a Director and Chief Innovation Officer from December 2018 to January 2020, prior to its sale to Novartis in January 2020. Prior to his founding of The Medicines Company, Dr. Meanwell was a Partner at MPM Capital, a venture capital firm. Before then, he held leadership roles of increasing scope at Roche worldwide, culminating as Senior Vice President and Director in the pharmaceutical division. Dr. Meanwell began his career in cancer treatment and research. He holds an M.B., Ch.B. and M.D. magna cum laude from the University of Birmingham, United Kingdom.